Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.
Research follows a trend in targeting not only the faulty genetics of cancer but also the tumor microenvironment.
Anne Boyer, a poet and essayist, writes about her experience with triple-negative breast cancer in “The Undying.”
Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.
A study looked at circulating tumor DNA as a biomarker for health outcomes among women with triple-negative breast cancer.
An annual campaign to increase awareness of the disease.
National Mammography Day is observed the 3rd Friday of October since 1993.
Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.
When therapist Clare Reed, of Dublin, was diagnosed with breast cancer, she used her therapeutic skills to change her own life.
“Don’t eat me” proteins are “like invisibility cloaks for the cancer,” preventing white blood cells from detecting and devouring tum...
Until now, there had been little opportunity to note the effects of anti-estrogen therapy on brain metastases resulting from breast cancer.
Tecentriq plus Abraxane was approved under accelerated approval based on progression-free survival.
ORR, PFS, TTP…we help you sort out what they mean.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.